Os therapies announces phase 2b clinical trial of ost-her2 achieves primary endpoint with statistical significance in the prevention of recurrent, fully resected, lung metastatic osteosarcoma

New york--(business wire)--os therapies, inc. (nyse-a: ostx), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a phase 2b clinical trial (nct04974008) of ost-her2 (ost31-164) - the company's her2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. the data demonstrate statistically significant res.
OST Ratings Summary
OST Quant Ranking